AMEX · NSRX
Healthcare · Biotechnology
$3.62
Up+$0.42 (+13.12%)
Updated Aug 15, 2026, 3:09 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
NSRX closed at $3.62 after 21 trading sessions, up 20.27% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $3.20 | $3.64 | $3.20 | $3.62 | 27.45K |
| Aug 13, 2026 | $3.08 | $3.49 | $3.05 | $3.20 | 6.84K |
| Aug 12, 2026 | $3.186 | $3.2384 | $3.13 | $3.2384 | 3.14K |
| Aug 11, 2026 | $3.40 | $3.40 | $3.2241 | $3.31 | 4.11K |
| Aug 10, 2026 | $3.26 | $3.51 | $3.21 | $3.35 | 15.39K |
| Aug 7, 2026 | $3.18 | $3.57 | $3.14 | $3.455 | 9.37K |
| Aug 6, 2026 | $3.22 | $3.4999 | $3.10 | $3.39 | 11.66K |
| Aug 5, 2026 | $3.47 | $3.57 | $3.15 | $3.32 | 19.89K |
| Aug 4, 2026 | $3.20 | $3.60 | $3.15 | $3.50 | 70.57K |
| Aug 3, 2026 | $3.04 | $3.19 | $2.97 | $3.19 | 8.25K |
| Jul 31, 2026 | $2.96 | $3.22 | $2.96 | $3.03 | 5.74K |
| Jul 30, 2026 | $3.02 | $3.19 | $3.02 | $3.18 | 2.44K |
| Jul 29, 2026 | $2.98 | $3.25 | $2.97 | $3.21 | 12.57K |
| Jul 28, 2026 | $2.96 | $3.15 | $2.96 | $3.03 | 16.56K |
| Jul 27, 2026 | $3.08 | $3.10 | $2.9601 | $3.09 | 12.34K |
| Jul 24, 2026 | $2.92 | $3.15 | $2.92 | $3.12 | 37.21K |
| Jul 23, 2026 | $2.90 | $3.093 | $2.8704 | $3.093 | 9.65K |
| Jul 22, 2026 | $2.90 | $3.06 | $2.90 | $2.91 | 6.09K |
| Jul 21, 2026 | $3.03 | $3.03 | $3.02 | $3.03 | 5.46K |
| Jul 20, 2026 | $2.96 | $3.02 | $2.96 | $3.01 | 4.58K |
| Jul 17, 2026 | $2.93 | $3.096 | $2.93 | $3.01 | 6.77K |
The latest Smart Investors Daily articles mentioning NSRX.
NSRX research
Company profile and research snapshot.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 26, 2026 | Citizens | Market Outperform | — |
| Dec 18, 2025 | Citizens | Market Outperform | — |
| Sep 29, 2025 | Laidlaw & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 28, 2026
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the
Benzinga · Jun 9, 2026
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a
Yahoo · Jun 1, 2026
TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, June 10, 2026 at 8:00 AM ET featuring Michael S. Blaiss, MD (Medical College of Georgia, Good Samaritan Health Center of Gwinnett) and Joel Brooks, DO, MPH (Columbia University Vagelos Coll
Yahoo · May 1, 2026
TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences. Market Movers Investor SummitMay 5, 2026, New York, NYChief Financial Officer Eyal Rubin will participate in 1x1 meetings. D. Boral Capital Global ConferenceMay 7, 2026, New York, NYChief Fi
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NSRX.
No results
No recent SID articles mention NSRX.
